evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

23 questions · 24 findings · 3 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 8.3%GRADE not reported 5 · 20.8%Very low 0 · 0%Low 9 · 37.5%Moderate 5 · 20.8%High 3 · 12.5%

Chondroitin vs placebo

Pain on a 0 to 100 mm scale ‐ Short‐term studies (< 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis
1 finding from 1 review

Chondroitin vs placebo

Pain on a 0 to 100 scale ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis
1 finding from 1 review

Chondroitin vs placebo

WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis

Chondroitin leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term… compared with placebo (high certainty).

1 finding from 1 review

Chondroitin vs placebo

Radiographic Outcome: Reduction in Minimum Joint Space Width (JSW) in mm ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d Scale: millimeters (smaller decrease in reduction in minimum joint space width is better) · patients with osteoarthritis
1 finding from 1 review

Chondroitin vs placebo

Withdrawals due to adverse events · patients with osteoarthritis

Chondroitin showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Chondroitin vs placebo

Number of serious adverse events · patients with osteoarthritis

Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Chondroitin with or without glucosamine vs placebo or control

WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d · patients with osteoarthritis

Chondroitin with or without glucosamine leads to higher WOMAC MCII Pain subscale (reduction in knee pain by 20%) Long‐term… compared with placebo/control (high certainty).

1 finding from 1 review

Oral glucosamine hydrochloride/chondroitin sulphate vs placebo

Pain on TMJ palpation (ordinal scale) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

Oral glucosamine hydrochloride/chondroitin sulphate showed no clear difference in pain on TMJ palpation (ordinal scale) compared with placebo; GRADE not reported.

1 finding from 1 review

Oral glucosamine hydrochloride/chondroitin sulphate vs placebo

Total pain rating index (McGill Pain Questionnaire) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

Oral glucosamine hydrochloride/chondroitin sulphate showed no clear difference in total pain rating index (McGill Pain Questionnaire) compared with placebo; GRADE not reported.

1 finding from 1 review

Oral glucosamine hydrochloride/chondroitin sulphate vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review

Oral glucosamine hydrochloride/chondroitin sulphate vs placebo

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

Oral glucosamine hydrochloride/chondroitin sulphate showed no clear difference in pain intensity (VAS) compared with placebo; GRADE not reported.

1 finding from 1 review